REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Update

REGENXBIO Inc. (NASDAQ:RGNX) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 6,230,000 shares, an increase of 18.4% from the November 30th total of 5,260,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 6.1 days.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RGNX shares. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a research report on Wednesday, December 11th. HC Wainwright dropped their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. Finally, Raymond James restated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.27.

REGENXBIO Trading Up 4.1 %

REGENXBIO stock traded up $0.30 during midday trading on Tuesday, hitting $7.53. The stock had a trading volume of 430,598 shares, compared to its average volume of 720,221. The stock has a market cap of $373.07 million, a P/E ratio of -1.50 and a beta of 1.24. REGENXBIO has a 12 month low of $7.14 and a 12 month high of $28.80. The business has a fifty day moving average price of $9.21 and a 200 day moving average price of $10.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Integral Health Asset Management LLC increased its stake in shares of REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after purchasing an additional 190,000 shares during the last quarter. Barclays PLC raised its holdings in REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 67,948 shares in the last quarter. Quest Partners LLC lifted its position in shares of REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock worth $491,000 after buying an additional 41,645 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 17,533 shares in the last quarter. Finally, Squarepoint Ops LLC increased its holdings in shares of REGENXBIO by 630.9% during the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock valued at $1,711,000 after acquiring an additional 126,249 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors and hedge funds.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.